For­mer Viela CEO Bing Yao finds his next gig — bring­ing Chi­nese R&D in­no­va­tion state­side

When Hori­zon Ther­a­peu­tics bought out Viela Bio for $53 a share, every­one won­dered what then-CEO Bing Yao would do next — in­clud­ing him­self. Three months af­ter the sale was com­plet­ed, we have an an­swer.

Yao launched Ar­riVent Bio­phar­ma on Wednes­day with up to $150 mil­lion in fund­ing and an EGFR-tar­get­ed ty­ro­sine ki­nase in­hibitor in-li­censed from Shang­hai-based Al­list Phar­ma­ceu­ti­cals. His goal? To bring in­no­va­tions from Chi­na and oth­er emerg­ing biotech hubs to the US, EU and be­yond.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER